Celldex and ImmunoCellular fall and rise on hype and hope
If Celldex was hoping that "promising" interim data from an ongoing phase II study with rindopepimut (CDX-110) in glioblastoma would be enough to reassure investors about the cancer vaccine’s potential, it will have been disappointed by yesterday’s share price reaction: the company's stock fell 10%. ...
Orexigen sees Light at the end of the tunnel
With positive results of Contrave’s cardiovascular outcomes study under its belt Orexigen Therapeutics should look forward to a reasonably quick US approval and an interesting advantage in Europe over its two obesity rivals, Arena Pharmaceuticals and Vivus. ...
EP Vantage interview – Prosensa braces itself for Glaxo verdict
Prosensa’s future hangs in the balance after the damaging phase III failure of its lead exon-skipping project, drisapersen, but at least for now the group can count on the support of its partner GlaxoSmithKline. ...
Immuno-oncology buzz awakens Roche’s interest in cancer vaccines
The cancer vaccine space might still be waiting for a real phase III success story, but this has not stopped Roche moving in on a couple of early-stage projects. The potential to combine these immune targeting therapies with emerging immuno-oncology molecules has prompted the Swiss pharma’s interest. ...
Terms & Conditions
Follow us on Twitter